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SUMMARY
A complex interplay of environmental factors impacts the metabolism of human cells, but neither 
traditional culture media nor mouse plasma mimic the metabolite composition of human plasma. 
Here, we developed a culture medium with polar metabolite concentrations comparable to those of 
human plasma (human plasma-like medium; HPLM). Culture in HPLM, relative to that in 
traditional media, had widespread effects on cellular metabolism, including on the metabolome, 
redox state, and glucose utilization. Among the most prominent is an inhibition of de novo 
pyrimidine synthesis – an effect traced to uric acid, which is 10-fold higher in the blood of humans 
than of mice and other non-primates. We find that uric acid directly inhibits UMP synthase and 
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consequently reduces the sensitivity of cancer cells to the chemotherapeutic agent 5-fluorouracil. 
Thus, media that better recapitulates the composition of human plasma reveals unforeseen 
metabolic wiring and regulation, suggesting that HPLM should be of broad utility.
Graphical abstract
Mimicking the metabolite composition of human plasma in culture reveals new tumor specific 
liabilities and metabolite-drug interactions
INTRODUCTION
There is a resurgence of interest in the metabolism of mammalian cells and in understanding 
the metabolic adaptations that enable cells to grow and proliferate (DeBerardinis et al., 
2008; Hosios et al., 2016; Keibler et al., 2016; Lunt and Vander Heiden, 2011; MacIver et 
al., 2013; Pearce et al., 2013; Vander Heiden et al., 2009). Cells in culture are commonly 
used to study metabolism (DeBerardinis and Chandel, 2016) and despite the appreciation 
that metabolic networks are flexible (Boroughs and DeBerardinis, 2015; Cairns et al., 2011; 
Cantor and Sabatini, 2012; Lehuede et al., 2016; Olson et al., 2016) and greatly influenced 
by environmental metabolites (Davidson et al., 2016; DeBerardinis and Chandel, 2016; 
DeNicola and Cantley, 2015; Hensley et al., 2016; Maddocks et al., 2013; Mayers et al., 
2016; Yuneva et al., 2012), there has been relatively little investigation of how the small 
molecule composition of culture media impacts metabolism.
Traditional synthetic cell culture media were not developed with the primary desire of 
mimicking human plasma, but, rather, to address the need for large amounts of medium with 
less inherent variability than natural media such as biological fluids and tissue extracts 
(Freshney, 2010). Upon defining the minimum nutritional requirements of two cell types 
(Eagle, 1955a; 1955b), Eagle formulated one of the first standardized synthetic media, Basal 
Medium Eagle (BME), over half a century ago (Eagle, 1955c). Soon after, Eagle developed 
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Minimal Essential Medium (MEM) (Eagle, 1959), and within the ensuing decade, Dulbecco 
and Freeman formulated DMEM (Dulbecco’s Modified Eagle Medium) originally for the 
culture of mouse embryonic cells (Dulbecco and Freeman, 1959), and Moore and colleagues 
developed RPMI 1640 for that of blood cells (Moore et al., 1967). Even though the nutrient 
concentrations of DMEM and RPMI 1640 poorly resemble those of human plasma, most 
studies of metabolism examine cells cultured in these media.
Efforts have been made to adjust the concentrations of media components, usually one or 
several nutrients at a time, to better reflect physiologic conditions (Birsoy et al., 2014; 
Favaro et al., 2012; Kamphorst et al., 2015; Pan et al., 2016; Schug et al., 2015; Tardito et 
al., 2015; Yao et al., 2016). Most such modified media not only contain other nutrients at 
non-physiological levels, but also lack defined concentrations of many metabolites now 
known to be present in human plasma. In mice and humans, great progress has been made in 
the study of metabolism in vivo, usually by monitoring the utilization patterns of isotope-
labeled nutrients in tumors or normal tissues (Comerford et al., 2014; Commisso et al., 
2013; Davidson et al., 2016; Hensley et al., 2016; Mashimo et al., 2014; Mayers et al., 2016; 
Sellers et al., 2015; Venneti et al., 2015; Yuneva et al., 2012). While such models provide a 
physiologically relevant environmental context for the study of metabolism, they do not 
permit the scope and flexibility of experimentation possible in cultured cells. In addition, 
there are multiple examples of differences in the metabolism of mice and humans (Adelman 
et al., 1988; Chandrasekera and Pippin, 2014; Demetrius, 2005; Elsea and Lucas, 2002; 
Martignoni et al., 2006), and it is unclear how well the metabolite composition of murine 
plasma reflects that of humans.
Here, we developed a medium with a defined set of metabolites and salts at the 
concentrations reported for adult human plasma (human plasma-like medium; HPLM). 
Culture in HPLM dramatically alters the metabolism of cells compared to that in traditional 
media. Among its most prominent effects is an inhibition of de novo pyrimidine synthesis, 
which we traced to uric acid – a metabolite whose plasma concentration is up to an order of 
magnitude greater in higher primates than in other mammals (Álvarez-Lario and Macarrón-
Vicente, 2010; Kratzer et al., 2014; Wu et al., 1992). We find that uric acid directly inhibits 
UMP synthase (UMPS), and consequently, reduces the sensitivity of cancer cells to the 
chemotherapeutic agent 5-fluorouracil. While we traced the effects of HPLM on pyrimidine 
metabolism to uric acid, the causes for most of the metabolic effects we observe are 
unknown and of potential interest for future study.
RESULTS AND DISCUSSION
A cell culture medium that reflects the polar metabolite composition of human plasma
The classic synthetic cell culture media, BME, MEM, DMEM, and RPMI 1640, contain 
glucose, amino acids, vitamins, and salts at concentrations that in large part do not reflect 
those of human plasma (Figure 1A, Table S1). These media also lack additional components 
revealed to be present by mass spectrometric and NMR analyses of plasma (Psychogios et 
al., 2011). Instead, basal media are often supplemented with heat inactivated fetal bovine 
serum (IFS), which contributes an undefined and often unaccounted for cocktail of 
metabolites, as well as the growth factors and hormones needed for cell proliferation 
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(Freshney, 2010). Thus, while the impact of environmental factors on cell metabolism is well 
appreciated (Davidson et al., 2016; DeNicola and Cantley, 2015; Hensley et al., 2016; 
Maddocks et al., 2013; Mayers et al., 2016; Yuneva et al., 2012), the interrogation of 
cultured cells in media that better reflect the metabolite composition of human plasma is 
largely unexplored (Figure 1B).
To begin to address this, we developed a culture medium with a defined collection of 
metabolites and salt ions at concentrations reported for plasma from healthy adult humans 
(human plasma-like medium; HPLM) (Psychogios et al., 2011; Wishart et al., 2013). 
Although some serum-free media have entirely defined recipes, they often require 
meticulous tailoring of growth factors to support the culture of different cell types (Freshney, 
2010). Thus, given our hope that HPLM will be of broad utility, we supplemented it with 
10% dialyzed IFS (HPLM+dIFS) to add the growth factors and hormones required for the 
proliferation of a broad range of cells, while minimizing the addition of polar metabolites at 
unknown concentrations. We did not attempt to recapitulate the lipophilic components of 
human serum because the removal of serum lipids present at otherwise unknown 
concentrations requires a charcoal stripping step that can deplete certain hormones and 
growth factors. As anticipated, dialyzed IFS contains total, LDL, and HDL cholesterol at 
concentrations equivalent to those in IFS (Table S1). The Supplemental Experimental 
Methods describes HPLM+dIFS in detail, but, in brief, it contains glucose, proteinogenic 
amino acids, salts, twenty-seven additional polar metabolites, 10% dialyzed IFS and 
vitamins at the same concentrations as RPMI 1640 (Figure 1C, Table S1); uses a bicarbonate 
buffering system at physiological pH; and has an osmolality of ~295 mOsm/kg.
Because RPMI 1640 (herein RPMI) is the medium of choice for culturing normal blood 
cells as well as the hematological cancer cells we examine in detail below (Freshney, 2010; 
Moore et al., 1967), we chose it as the reference medium for comparing the effects of 
HPLM+dIFS on cells. We generated two RPMI formulations, each with physiological glucose 
(5 mM), but supplemented with either 10% IFS (RPMI+IFS) or 10% dialyzed IFS 
(RPMI+dIFS). Metabolite profiling confirmed that the dialysis of IFS substantially reduced 
its levels of polar metabolites, but had little effect on its lipid contents (Figure 1D, Table S1). 
Moreover, it also revealed that fetal bovine serum poorly reflects the metabolic composition 
of adult human plasma, as the addition of 10% IFS to RPMI did not yield concentrations for 
many metabolites at 10% of the reported values in human plasma. Similarly, while the 
concentrations of glucose and many amino acids in mouse plasma in large part resemble 
those in human plasma, those of other metabolites were very different, including examples 
that were at least 3–10-fold lower (e.g. carnitine and uric acid) or greater (e.g. 3-
hydroxybutyrate and taurine) in mouse plasma (Figure 1D, Table S1). Thus, while murine 
tumor models are useful for studying metabolism in the context of stromal and immune 
cells, HPLM+dIFS more closely reflects the polar metabolite composition of human plasma 
than does mouse plasma.
HPLM+dIFS provides the metabolites needed for cancer cell proliferation, as six cell lines 
representing various human hematological cancers as well as four cell lines from diverse 
human epithelial cancers proliferated in HPLM+dIFS at rates that were comparable, albeit 
generally lower, to those in RPMI+IFS and RPMI+dIFS (Figure 1E, Figure S1A). HPLM+dIFS 
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also supports efficient viral-based transduction (Figure S1B), and cells cultured in 
HPLM+dIFS activated mTORC1 signaling to an extent comparable to those in RPMI+IFS, as 
detected by phosphorylated S6K1 (Figure S1C).
Culture of cells in HPLM extensively alters their metabolic landscape and fate of glucose 
carbons
To test the hypothesis that culturing cells in a medium that better mimics the metabolic 
composition of human plasma alters cellular metabolism compared to that in established 
media, we began by comparing the metabolite profiles of cells cultured in HPLM+dIFS to 
those in RPMI+IFS or RPMI+dIFS. Indeed, HPLM+dIFS profoundly affected the intracellular 
abundances of many metabolites across multiple pathways, including amino acid, lipid, and 
nucleotide metabolism (Figure 2A, Table S2). For several metabolites, such as arginine, 
asparagine, and taurine, the differences reflected those in the media themselves, while for 
others, such as aspartate and lactate, they did not. Most HPLM+dIFS-induced changes were 
shared by all six of the cell lines examined, but some were cell line-specific, underscoring 
how the heterogeneity of cancer (Cantor and Sabatini, 2012; Eason and Sadanandam, 2016; 
Hu et al., 2013; Shaul et al., 2016) can influence the cellular responses to environmental 
conditions. For example, whereas HPLM+dIFS reduced argininosuccinate abundance in five 
cell lines, it increased it in P12-Ichikawa cells. Similarly, HPLM+dIFS caused dramatic 
elevations in fructose-6-phosphate/glucose-1-phosphate (F6P/G1P) only in K562, P12-
Ichikawa, and SUDHL4 cells, and modest reductions in oxoglutarate only in KMS12BM 
cells. Culture in HPLM+dIFS also induced widespread and largely similar alterations to the 
metabolomes of several other cell types, including a variety of epithelial cancer cell lines 
(786-0, A549, MCF7, and SW620), an early passage undifferentiated sarcoma cell line 
(CLF-PED-015T (Hong et al., 2016)), a normal foreskin fibroblast cell line (BJ), and a 
primary acute myeloid leukemia sample (Figure S2A, Table S3).
Culture in HPLM+dIFS did not affect the energy charge (Atkinson, 1968) in any cell line 
(Figure 2B), but did have cell line-specific effects on the redox state as reflected by changes 
to the ratios of two redox couples: GSH/GSSG (Figure 2C) and NAD/NADH (Figure 2D). 
HPLM+dIFS did not markedly alter the correlation between rates of glucose consumption and 
lactate secretion across four cell lines examined (Figure S2B), suggesting that it had little 
effect on the aerobic glycolysis phenotype common to most cancer cells (Hosios et al., 2016; 
Jain et al., 2012). In contrast, HPLM+dIFS reduced basal oxygen consumption rates in two of 
the same four cell lines, revealing a cell line-specific impact on mitochondrial respiration 
(Figure S2C). Lastly, the levels of defined components in HPLM+dIFS and RPMI+IFS were 
largely unaffected following the culture of three cell lines in conditions identical to those 
used to obtain whole-cell metabolite profiles (Figure S2D, Table S3).
To specifically study glucose utilization, we compared the 13C-labeling patterns for several 
metabolites following the culture of three cell lines (K562, NOMO1, and P12-Ichikawa) in 
HPLM+dIFS containing [U-13C]-glucose to those in RPMI+IFS or RPMI+dIFS (Figure 3A, 
Table S2). Interestingly, while HPLM+dIFS contains pyruvate at a concentration of ~40 μM, 
which is over 10-fold greater than that of RPMI+IFS, it did not affect the fraction of pyruvate 
labeled with three 13C (M3) (Figure 3B). However, HPLM+dIFS did affect the metabolism of 
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glucose-derived Acetyl-CoA generated by the oxidation of pyruvate, as reflected by 
reductions in the M2 labeling of citrate in the TCA cycle and of certain acetylated amino 
acids (Figure 3C, Table S2). HPLM+dIFS also decreased the fraction of M3-
glycerophosphocholine, suggesting that it may induce alterations in glucose utilization for 
lipid synthesis (Figure 3D).
As with the metabolome, HPLM+dIFS also had cell-line dependent effects on glucose 
utilization. Among the most prominent was a dramatic reduction in the M6 labeling of 
F6P/G1P only in K562 and P12-Ichikawa cells (Figure 3E), suggesting that sources beyond 
exogenous glucose contribute to F6P/G1P pools when these cells are cultured in 
HPLM+dIFS. Additionally, while HPLM+dIFS contains alanine at ~620 μM, a concentration 
nearly 5-fold greater than that of RPMI+IFS, it did not affect the fraction of M3-alanine in 
two cell lines. However, it reduced by over 2-fold the M3 labeling of alanine in P12-
Ichikawa cells (Figure 3F), revealing that HPLM+dIFS impacts the fate of glucose-derived 
pyruvate in these cells. Nearly all these changes were also observed when comparing cells 
cultured in HPLM+dIFS to those in RPMI+dIFS, though greater discrepancies in the levels of 
certain exogenous metabolites, such as pyruvate and alanine, influenced their 
corresponding 13C labeling patterns (Figure S3A–E, Table S2).
To examine one aspect of cellular nitrogen metabolism, we compared the 15N-labeling 
patterns for several amino acids following culture of the same three cell lines in HPLM+dIFS 
containing [α-15N]-glutamine to those in RPMI+IFS or RPMI+dIFS (Figure 3G, Table S2). 
Interestingly, large differences in amino acid concentrations between HPLM+dIFS and 
RPMI+IFS influenced corresponding 15N labeling patterns in a cell line-dependent manner. 
For example, while HPLM+dIFS contains a higher alanine concentration than RPMI+IFS, it 
reduced the fraction of alanine labeled with one 15N (M1), but only in NOMO1 and P12-
Ichikawa cells (Figure 3H). Similarly, though HPLM+dIFS contains asparagine at a 
concentration of 50 μM, which is nearly 7-fold less than that of RPMI, it dramatically 
increased the fraction of M1-asparagine, but only in K562 and NOMO1 cells (Figure 3I). In 
addition, despite containing valine at a concentration roughly equivalent to that of RPMI, 
HPLM+dIFS nonetheless increased the fraction of M1-valine, but only in K562 and P12-
Ichikawa cells (Figure 3J), suggesting it affects the transaminase-mediated transfer of α-15N 
from glutamine to various amino acids in a cell line-dependent manner. Nearly all these 
changes were also observed when comparing cells cultured in HPLM+dIFS to those in 
RPMI+dIFS, though a greater discrepancy in the level of exogenous alanine influenced its 
corresponding 15N labeling pattern (Figure S3F–H, Table S2).
Collectively, these data reveal that while aerobic glycolysis was essentially unaffected, 
culture in HPLM+dIFS, compared to that in RPMI, had widespread effects on the metabolic 
landscape of cells. These include alterations to the metabolome, redox state, mitochondrial 
respiration, glucose utilization, and nitrogen metabolism, and were either common to all cell 
lines tested or were cell line-specific. While the causes for many of the changes are 
unexplained, they do reveal the profound impact of media composition on cellular 
metabolism.
Cantor et al. Page 6
Cell. Author manuscript; available in PMC 2018 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The uric acid component of HPLM has striking effects on de novo pyrimidine biosynthesis
Among the most dramatic consequences of culture in HPLM+dIFS compared to that in 
RPMI, were increases in the intracellular abundances of four metabolites involved in 
nucleotide metabolism: carbamoylaspartate, dihydroorotate, orotate, and orotidine (Figure 
4A–D). As none of the four could be detected in either medium, the cause of these changes 
was not immediately apparent. The first three are intermediates in the de novo pyrimidine 
biosynthesis pathway that generates UMP, while orotidine is the dephosphorylation product 
of OMP, which is the immediate precursor to UMP in this pathway (Figure 4E). In four of 
the six cell lines examined, culture in HPLM+dIFS also reduced by 40–60% the intracellular 
levels of the UTP and CTP pyrimidine nucleotides (Figure 4F–G), but did not have similar 
effects on purine nucleotides (Figure S4). Cell line-dependent contributions of salvage 
pathway activities (Evans and Guy, 2004) or altered consumption of pyrimidine nucleotide 
pools may explain why HPLM+dIFS does not decrease the abundance of pyrimidine 
nucleotides in all cells.
To determine which component(s) of HPLM+dIFS affects the de novo pyrimidine synthesis 
pathway, we cultured K562 cells in HPLM+dIFS derivatives lacking: (1) acetone, creatine, 
creatinine, formate, fructose, galactose, glutathione, glycerol, and hypoxanthine; (2) non-
proteinogenic amino acids (8 metabolites); (3) water-soluble acids (8 metabolites); (4) urea; 
or (5) uric acid (Figure 5A). Remarkably, uric acid alone mediated the observed effects, as 
its removal from HPLM+dIFS reduced orotate and orotidine levels to those of cells cultured 
in RPMI (Figure 3C–D) or in minimal HPLM, which lacks the twenty-seven components 
collectively missing from the dropout formulations (Figure 5B). HPLM+dIFS contains uric 
acid at 350 μM, a concentration that is 40- and at least 500-fold greater than that of 
RPMI+IFS and RPMI+dIFS, respectively (Figure 5C), and, importantly, its intracellular 
concentration reflects that of the corresponding culture medium (Figure 5D). In K562 cells, 
uric acid dose-dependently increased orotate and orotidine abundances (Figure 5E), and at 
its highest tested concentration (700 μM), led to a detectable accumulation of OMP. The 
addition of 350 μM uric acid to RPMI+IFS also greatly boosted orotate and orotidine levels, 
but, like complete HPLM, had cell line-dependent effects on UTP abundance (Figure 5F). 
Lastly, the closely related molecule 9-methyluric acid (9-MUA) entered K562 cells (Table 
S2), but did not alter the levels of orotate, orotidine, or the other intermediates in the de novo 
pyrimidine biosynthesis pathway (Figure 5G).
The effects of uric acid on pyrimidine metabolism are particularly interesting because its 
plasma concentrations are up to an order of magnitude greater in humans, chimpanzees, 
gorillas, and additional higher primates than in other mammals (Álvarez-Lario and 
Macarrón-Vicente, 2010; Kratzer et al., 2014; Wu et al., 1992). Whereas most mammalian 
species, including mouse and cow, metabolize uric acid to allantoin via the liver enzyme 
uricase, the gene encoding uricase (UOX) became inactivated via pseudogenization during 
hominid evolution (Kratzer et al., 2014; Oda et al., 2002; Wu et al., 1992; 1989). As a 
consequence, uric acid, rather than allantoin, is the end product of purine catabolism in 
many higher primates (Figure 5H). Furthermore, in mice, which have a plasma uric acid 
concentration of ~30 μM, uricase activity is essential, given that most UOX-null mice die 
within four weeks of life from extreme hyperuricemia and nephropathy (Wu et al., 1994). 
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Thus, the finding that uric acid impacts the de novo pyrimidine biosynthesis pathway would 
have been difficult to make by studying cells growing in mice or cultured in conventional 
media.
Uric acid is a direct inhibitor of UMPS
In addition to boosting the intracellular levels of orotate and orotidine, HPLM also markedly 
increased their secretion into the media (Figure S5A–B) – a phenomenon reminiscent of the 
high urinary excretion of these metabolites in patients with orotic aciduria and orotidinuria. 
As this disorder can be caused by the genetic (Bailey, 2009; Fox et al., 1973; Smith et al., 
1961; Suchi et al., 1997) or pharmacological (Bono et al., 1964; Fallon et al., 1961; Fox et 
al., 1970; Kelley and Beardmore, 1970) inhibition of UMP synthase (UMPS), we considered 
the possibility that the uric acid component of HPLM leads to the inhibition of this enzyme 
in cells. UMPS is a bifunctional two-domain enzyme that catalyzes the final two steps of the 
de novo pyrimidine biosynthesis pathway to generate UMP (Jones, 1980). In the first step, 
the orotate phosphoribosyltransferase (OPRT) domain synthesizes OMP from orotate and 
PRPP, and in the second, the OMP decarboxylase (ODC) domain converts OMP to UMP 
(Figure 6A).
To pursue the idea that uric acid might cause inhibition of UMPS, we first asked if an 
established UMPS inhibitor had similar effects on the de novo pyrimidine biosynthesis 
pathway as uric acid in our cells. The small molecules allopurinol and 6-azauridine are 
prodrugs that, upon conversion into allopurinol ribonucleotide and 6-aza-UMP (Bono et al., 
1964; Handschumacher, 1960; Kelley and Beardmore, 1970; Murrell and Rapeport, 1986), 
respectively, competitively inhibit the ODC domain of UMPS (Figure 6B). Indeed, in K562 
cells, allopurinol dose-dependently increased the levels of carbamoylaspartate, 
dihydroorotate, orotate, orotidine, and OMP (Figure S6A–B). Moreover, at its highest tested 
concentration, allopurinol also decreased by nearly 30% the abundance of UTP in these cells 
(Figure S6C). Using LC/MS-based metabolite profiling, we detected a species whose mass-
to-charge ratio (m/z) matched the predicted m/z of allopurinol ribonucleotide, and whose 
magnitude correlated with the concentration of allopurinol in the media (Figure S6D). 
Importantly, this species could be distinguished from its isomer, IMP, by their differing 
chromatographic retention times. These data are consistent with the conversion of 
allopurinol to allopurinol ribonucleotide within the cell. However, despite substantial efforts, 
we failed to detect in cells a metabolite peak consistent with a putative uric acid 
ribonucleotide. Thus, we considered if uric acid itself might directly inhibit UMPS.
To investigate this possibility, we developed an in vitro UMPS activity assay containing 
recombinant UMPS (Figure S6E) and its substrates, orotate and PRPP, and verified its 
activity via the LC/MS detection of OMP and UMP (Figure 6C). A UMPS mutant (Y37A, 
R155A), which was designed based on a recently deposited structure of the OPRT domain of 
human UMPS (Protein Data Bank entry 2WNS, chains A and B) (Figure S6F), had no 
activity and served as a negative control in the assay. As anticipated, the established ODC 
inhibitor, 6-aza-UMP, dose-dependently decreased UMP production by UMPS, and at 50 
μM, reduced UMP levels to ~3% of those in reactions containing vehicle (Figure 6D). 6-aza-
UMP also dramatically increased the abundance of OMP, but the boost in OMP did not 
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tightly correlate with the decrease in UMP, perhaps owing to the known reversibility of the 
OPRT reaction (Traut and Jones, 1977).
Remarkably, uric acid also dose-dependently inhibited UMP production by UMPS, and, like 
6-aza-UMP, also increased OMP in a fashion that did not completely correlate with the 
decrease in UMP (Figure 6E). Uric acid was far less potent than 6-aza-UMP, as at 1 mM, it 
could only reduce UMP levels to ~30% of those in reactions containing vehicle. Importantly, 
however, uric acid inhibited UMPS in vitro at concentrations consistent with those that 
boosted orotate and orotidine levels in cultured cells. Lastly, allopurinol and 6-azauridine did 
not directly inhibit UMPS, and neither did 9-MUA or allantoin (Figure 6F).
Thus, we conclude that uric acid, at the concentrations present in human plasma, is a direct 
inhibitor of the ODC domain of UMPS.
Uric acid antagonizes the cytotoxicity of 5-fluorouracil
5-fluorouracil (5-FU) is an antimetabolite drug that, although developed over fifty years ago, 
remains widely used in the treatment of several types of cancer (Longley et al., 2003). In 
cells, 5-FU is metabolized into various fluoronucleotide derivatives that mediate its cytotoxic 
effects (Figure 7A). Among these is fluorouridine triphosphate (FUTP), which leads to cell 
death upon its misincorporation into RNA. FUTP synthesis begins with the conversion of 5-
FU to fluorouridine monophosphate (FUMP), either directly by the OPRT domain of UMPS 
or indirectly through the sequential activities of uridine phosphorylase and uridine kinase 
(Longley et al., 2003). Previous kinetic studies show that orotate competes with 5-FU for its 
direct conversion to FUMP by OPRT activity (Reyes and Guganig, 1975) (Figure 7B). 
Consistent with these findings, allopurinol reduces the sensitivity of certain cancer cell lines 
to 5-FU (Schwartz and Handschumacher, 1979), owing to orotate accumulation induced by 
competitive inhibition of the ODC domain of UMPS mediated by allopurinol ribonucleotide. 
Thus, we reasoned that uric acid might impact the sensitivity of cells to 5-FU through a 
similar mechanism.
Indeed, culture of NOMO1 cells in HPLM+dIFS increased the EC50 of 5-FU by ~5- and ~8-
fold compared to in RPMI+IFS and RPMI+dIFS, respectively (Figure 7C), without affecting 
the potency of doxorubicin – a DNA-damaging drug also commonly used in the treatment of 
cancer (Figure 7D). Moreover, removal of just uric acid from HPLM+dIFS reduced the EC50 
of 5-FU in NOMO1 cells by nearly 6-fold (Figure 7E), again without affecting doxorubicin 
sensitivity (Figure 7F). In cells treated with 5-FU and cultured in HPLM+dIFS lacking uric 
acid, we readily detected FUMP, fluorodeoxyuridine monophosphate (FdUMP), as well as 
5-FU (Figure 7G). While culture in uric acid-containing HPLM+dIFS had little effect on the 
intracellular abundances of FdUMP and 5-FU, it reduced FUMP levels below the limit of 
detection, consistent with the predicted antagonism of OPRT-mediated FUMP synthesis by 
orotate (Figure 7G).
As 5-FU is no longer used in the treatment of hematological cancers, we also asked if uric 
acid affects the 5-FU sensitivity of a more clinically relevant cancer cell line (Longley et al., 
2003). As in the six hematological cancer cell lines, culture of the SW620 colorectal cancer 
cell line in HPLM+dIFS increased the intracellular abundance of orotate (Figure S7A), 
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indicating that uric acid might also affect the 5-FU sensitivity of these cells. Indeed, removal 
of just uric acid from HPLM+dIFS reduced the 5-FU EC50 of SW620 cells by 3-fold relative 
to that in HPLM+dIFS (Figure S7B), but did not influence doxorubicin sensitivity (Figure 
S7C).
Thus, at concentrations found in human plasma, the endogenous metabolite uric acid affects 
the sensitivity of cancer cells to a common chemotherapeutic (Figure 7H). It is interesting to 
consider whether manipulations of plasma uric acid levels, such as by administration of 
uricase (Jeha et al., 2004), could improve the 5-FU sensitivity of human tumors that generate 
FUMP via OPRT-mediated synthesis.
CONCLUSIONS
Although the impact of environmental factors on cell metabolism is increasingly 
appreciated, traditional culture media and mouse plasma poorly reflect the metabolite 
composition of human plasma. Cell culture in a new medium, which better reflects the polar 
metabolite composition of human plasma (HPLM+dIFS), had widespread effects on cellular 
metabolism compared to that in established media. Among the most dramatic were 
alterations in the intracellular abundance of metabolites involved in pyrimidine metabolism. 
We ultimately traced this effect to uric acid, whose plasma concentration is up to an order of 
magnitude greater in humans than in most other mammals, including mouse and cow 
(Álvarez-Lario and Macarrón-Vicente, 2010; Kratzer et al., 2014; Wu et al., 1992). We find 
that uric acid, at concentrations present in human plasma, is an endogenous inhibitor of 
UMPS, which catalyzes the final two steps of the de novo pyrimidine biosynthesis pathway. 
Similar to other small molecule inhibitors of UMPS, uric acid induces an accumulation of 
orotate, which in turn, antagonizes the metabolism of 5-FU to the fluoronucleotide 
derivatives that mediate its cytotoxic effects.
Through the use of HPLM, we uncovered a role for an endogenous metabolite that would 
have been difficult to discover by studying cells cultured in established media or in mouse 
models (Wu et al., 1994). Although the causes of the many other changes to the metabolic 
landscape induced by HPLM are unexplained, they do reveal the impact of media 
composition on cellular metabolism, and suggest the potential to generate HPLM derivatives 
that reflect plasma metabolite conditions associated with particular pathophysiological states 
or lifestyles. Moreover, in the future it will be interesting to generate HPLM derivatives with 
additional components, such as proteins and lipids, at concentrations resembling those of 
adult human plasma, and to consider how HPLM affects other biological processes, 
including cellular differentiation. We conclude that HPLM should be of broad utility to 
study cellular metabolism and may help reveal new tumor-specific liabilities or metabolite-
drug interactions that are influenced by environmental metabolic composition.
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact David M. Sabatini (sabatini@wi.mit.edu).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Collection of Mouse Plasma
The MIT Institutional Animal Care and Use Committee approved procedures used for the 
collection of whole blood. Male C57Bl/6J mice, 3.5 months old, were maintained on regular 
chow at the specific pathogen free animal facility of the Whitehead Institute, and were fasted 
for 18 hr prior to blood collection. At 10:00 AM, 100 μL of blood was collected into 
heparinized tubes (Sarstedt Microvette 200 LH) from the facial vein, and the plasma fraction 
was collected following centrifugation at 850 g for 6 min at 4°C.
Collection of Human Plasma
At 6:00 AM, 10 mL of blood from the corresponding author (male, 48 years old) was 
collected into a heparinized tube (BD Vacutainer 366480) from the antecubital vein. Upon 
transferring 100 μL of blood to a fresh heparinized tube (Sarstedt Microvette 200 LH), the 
plasma fraction was collected following centrifugation at 850 g for 6 min at 4°C.
Primary cell isolation
A primary human acute myeloid leukemia specimen (estimated blast percentage of 80%; 
CD33+ CD13+ MPO−, CD117+, CD34+, HLA-DR+, CD71dim+) was collected from the 
bone marrow of a patient (male, 73 years old) at the Massachusetts General Hospital (MGH) 
as approved by the MGH Institutional Review Board. To remove red blood cells (RBCs), the 
specimen was added to a 20X volume of RBC lysis buffer (BioLegend 420301) and mixed 
well at room temperature. After 15 min incubation, cells were centrifuged at 650 g for 5 min 
at room temperature, resuspended in 5 mL PBS, again centrifuged using the same settings, 
and finally, resuspended in 2.5 mL PBS.
Cell lines
The following cell lines were kindly provided by: K562 and NOMO1, Dr. James Griffin 
(Dana Farber Cancer Institute); P12-Ichikawa, Dr. A. Thomas Look (Dana Farber Cancer 
Institute); SUDHL4, Dr. Margaret Shipp (Dana Farber Cancer Institute); KMS-12-BM and 
SEM, the Cancer Cell Line Encyclopedia (Broad Institute); CLF-PED-015T, Dr. Andrew 
Hong (Broad Institute); and BJ, Dr. Nir Hacohen (Broad Institute). Remaining cell lines 
(786-0, A549, MCF7, and SW620) were purchased from ATCC. Cell lines were verified to 
be free of mycoplasma contamination (Freshney, 2010) and the identities of all cell lines 
other than CLF-PED-015T (received at passage 7) and BJ (received at passage 1) were 
authenticated by STR profiling. We note the STR profile for SW620 cells revealed very 
minor background at 2 of the 10 loci evaluated, perhaps as a consequence of genetic drift 
over the course of passaging.
Cell culture conditions
Cells were primarily cultured in the following media:
1. RPMI+IFS: RPMI 1640 lacking glucose (Thermo Fisher Scientific 11879020) to 
which we added 5 mM glucose, 10% heat inactivated fetal bovine serum (IFS), 
penicillin, and streptomycin.
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2. RPMI+dIFS: RPMI 1640 lacking glucose (Thermo Fisher Scientific 11879020) to 
which we added 5 mM glucose, 10% dialyzed IFS, penicillin, and streptomycin.
3. HPLM+dIFS: HPLM (See Table S1) to which we added 10% dialyzed IFS, RPMI 
1640 100X Vitamins (Sigma-Aldrich R7256), penicillin, and streptomycin.
Using SnakeSkin dialysis tubing, 3.5K MWCO, 35 mm (Thermo Fisher Scientific PI88244), 
IFS was dialyzed against a 20X volume of PBS. Dialysis was carried out for 48 hr at 4°C 
with a complete PBS exchange every 9–12 hr. Prior to use, all media were sterile filtered 
using bottle-top vacuum filters, cellulose acetate membrane, pore size 0.45 μm (Sigma-
Aldrich CLS430514).
Prior to experiments, cells were grown in the medium of interest for at least two passages 
unless otherwise noted. Cells were typically split in the range 1:3 to 1:5 into fresh medium. 
All cells were maintained at 37°C and 5% CO2.
For the short-term culture of primary AML cells, media were supplemented with 50 μM β-
mercaptoethanol (Thermo Fisher Scientific 21985023), 100 ng/mL human SCF (Peprotech 
300–07), 10 ng/mL human IL-3 (Peprotech 200–03), 20 ng/mL human IL-6 (Peprotech 200–
06), 10ng/mL human TPO (Peprotech 300–18), and 10 ng/mL FLT3L (Peprotech 300–19).
For HEK-293T transfection experiments, cells were cultured in DMEM supplemented with 
10% IFS, penicillin, and streptomycin.
METHOD DETAILS
Plasmid construction
All plasmids and primers used in this study are described in Table S4. All plasmids 
generated in this study are deposited in Addgene.
Construction of lentiviral plasmid pLJC2-Rap2A-3xFLAG—The KRASV12 gene 
was amplified from the pDONR223-KRASV12 template using the primers JC4/JC5, 
digested with AgeI-BamHI, and cloned into pLJM1-eGFP to generate pLJM1-
KRASV12-3xFLAG. Plasmid pLJC1-KRASV12-3xFLAG was constructed using 
QuickChange PCR to remove two NotI sites of pLJM1-KRASV12-3xFLAG with the 
primers JC48/JC49 and JC50/JC51, respectively. The Rap2A gene was amplified from the 
pLJM1-Rap2A template using the primers JC68/JC69, digested with PacI-NotI, and cloned 
into pLJC1-KRASV12-3xFLAG to generate pLJC1-Rap2A-3xFLAG. The sequence 
encoding Rap2A-3xFLAG was then amplified from pLJC1-Rap2A-3xFLAG using the 
primers JC_LJC2-F/JC79, digested with AgeI-EcoRI, and cloned into pLJM1-eGFP to 
generate pLJM1-Rap2A-3xFLAG. Plasmid pLJC2-Rap2A-3xFLAG was then constructed 
using QuickChange PCR to remove two NotI sites of pLJM1-Rap2A-3xFLAG with the 
primers JC48/JC49 and JC50/JC51, respectively.
Construction of UMPS plasmids—The UMPS gene was amplified from the 
pDONR223-UMPS template using the primers JC624/JC625, digested with PacI-NotI, and 
cloned into pLJC2-Rap2A-3xFLAG to generate pLJC2-UMPS-3xFLAG. Plasmid pLJC2-
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UMPS (Y37A, R155A)-3xFLAG was constructed using a 2-step protocol based on overlap 
extension PCR methodology. In the first step, three fragments were amplified from the 
pLJC2-UMPS-3xFLAG template using the following primer pairs: JC_LJC2-F/JC716, 
JC715/JC720, and JC719/JC_LJC2-R. In the second step, the three fragments were pooled 
in a second PCR containing the primers JC_LJC2-F/JC_LJC2-R, then digested with PacI-
NotI, and cloned into pLJC2-UMPS-3xFLAG.
Design of HPLM
The Human Metabolome Database, which is integrated with the Serum Metabolome 
Database, (Psychogios et al., 2011; Wishart et al., 2013) contains 2,192 metabolites that 
were designated as being both detected and quantified in at least one human biofluid. From 
this collection, we removed molecules that met one of the following manually applied 
filtering criteria: (1) Metabolites for which a concentration in normal adult human blood was 
not indicated; (2) Lipophilic metabolites, including fatty acids, cholesterol, and derivatives 
of the following: cholesterol ester, ceramide, diglyceride, ganglioside, 
glycerophosphocholine, monoacylglyceride, phosphatidic acid, phosphatidylglycerol, 
phosphatidylinositol, phosphatidylserine, sphingomyelin, and triglyceride; (3) Metabolites 
with concentrations in normal adult human blood < 6 μM as denoted by at least one 
reference source; (4) Metabolites with concentrations in normal adult human blood indicated 
by only one reference source; and (5) Metabolites that were not commercially available. 
Although vitamins are among the nutritional requirements of cells in culture (Eagle, 1955c), 
most had annotated plasma concentrations that were well below the 6 μM threshold we set. 
Therefore, rather than omit these metabolites, we chose to supplement HPLM with a 
commercial concentrated mixture of vitamins at concentrations equivalent to those of RPMI 
1640. In addition, while trace elements such as copper and zinc are also essential for cells in 
culture, they are often contributed in sufficient quantities by transport molecules in IFS, such 
as albumin and insulin, and exceeding their necessary levels is often detrimental to cell 
proliferation (Sigma-Aldrich Media Expert; Online Resource). Thus, we did not include 
trace elements among the defined components of HPLM. Additional modifications, such as 
removal of non-endogenous compounds and gases, were also made to generate the final list 
of 20 proteinogenic amino acids, 27 additional polar metabolites, and 10 small ions included 
in the formulation of HPLM at concentrations similar to the calculated average of values 
reported for normal adult human blood. As anticipated, the metabolite concentrations of 
plasma collected from the corresponding author (See Collection of Human Plasma; Polar 
metabolite profiling and quantification of metabolite abundance) largely reflected those of 
HPLM. See Table S1.
Growth curves
For suspension cells, all cell lines were seeded at a density of 100,000 cells/mL in 12 mL 
culture medium and grown in 25 cm2 rectangular canted neck cell culture flasks (Westnet 
430639). Cell density measurements were recorded every 9–12 hr using a Beckman Z2 
Coulter Counter with a diameter setting of 8–30 μm. For each adherent cell line, 100,000 
total cells were seeded in 3 mL culture medium in each of nine technical replicates, and 
grown in 6-well plates. Every 9–12 hr, one replicate was aspirated, washed in 1 mL PBS, 
trypsinized, and used to analogously obtain cell density measurements.
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Points for time versus natural log-transformed cell density were plotted in GraphPad Prism 
and those comprising the exponential growth phase were fit using a linear regression 
equation. Specific growth rates were equivalent to slopes of the fit lines.
Polar metabolite profiling and quantification of metabolite abundance
LC/MS-based analyses were performed on a QExactive benchtop orbitrap mass 
spectrometer equipped with an Ion Max source and HESI II probe, which was coupled to a 
Dionex UltiMate 3000 UPLC system (Thermo Fisher Scientific). External mass calibration 
was performed using the standard calibration mixture every 7 days. Acetonitrile was LC/MS 
HyperGrade (EMD Millipore). All other solvents were LC/MS Optima grade (Thermo 
Fisher Scientific).
Media and Plasma—For metabolite profiling of media and plasma, samples were diluted 
1:40 in a solution containing 50% methanol, 30% acetonitrile, 20% water and either 
phenylalanine-d8 (Cambridge Isotope Laboratories DLM-1372) at 10 ng/mL or a mixture of 
17 isotope-labeled amino acids (Cambridge Isotope Laboratories MSK-A2-1.2) each at 909 
nM as internal standard(s) (Metabolite Composition of Cultured Media samples) and then 
stored at −80°C. Following a 5 min vortex and centrifugation at 21130 g for 5 min at 4°C, 2 
μL of each sample was injected onto a ZIC-pHILIC 2.1 × 150 mm analytical column 
equipped with a 2.1 × 20 mm guard column (both 5 μm particle size, EMD Millipore). 
Buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was 
acetonitrile. The chromatographic gradient was run at a flow rate of 0.150 mL/min as 
follows: 0–20 min: linear gradient from 80% to 20% B; 20–20.5 min: linear gradient from 
20% to 80% B; 20.5–28min: hold at 80% B. The mass spectrometer was operated in full 
scan, polarity-switching mode with the spray voltage set to 3.0 kV, the heated capillary held 
at 275°C, and the HESI probe held at 350°C. The sheath gas flow rate was set to 40 units, 
the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to 1 unit. The MS 
data acquisition was performed in a range of 70–1000 m/z, with the resolution set to 70,000, 
the AGC target at 106, and the maximum integration time at 20 msec.
Suspension cell lines—For metabolite profiling whole-cell suspension samples, cells 
were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 mL of 
fresh culture medium. After 24 hr incubation, cells were centrifuged at 250 g for 5 min, 
resuspended in 1 mL ice-cold 0.9% sterile NaCl (Bioexpress MSDW-1000), and again 
centrifuged at 250 g for 5 min at 4°C. Metabolites were extracted in a 1 mL solution of 80% 
methanol containing 10 ng/mL phenylalanine-d8 as an internal standard. Following a 10 min 
vortex and centrifugation for 3 min at 21130 g for 10 min at 4°C, samples were dried under 
nitrogen gas. Dried samples were stored at −80°C and then resuspended in 100 μL water. 
Following a 10 min vortex and centrifugation at 21130 g for 10 min at 4°C, 4 μL of each cell 
sample was injected for LC/MS analysis as described above for profiling media samples. For 
all experiments, an additional culture replicate was set up identically and used for measuring 
cell number and volume, which were each measured using a Beckman Z2 Coulter Counter 
with a diameter setting of 8–30 μm.
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Adherent cell lines—For metabolite profiling whole-cell adherent samples, cells were 
pelleted and then seeded at one of the following densities in 6-well plates in 3 mL of fresh 
culture medium: 70,000 cells/mL (786-0); 100,000 cells/mL (A549); 70,000 cells/mL 
(MCF7); 200,000 cells/mL (SW620); 80,000 cells/mL (BJ); and 100,000 cells/mL (CLF-
PED-015T). After 24 hr incubation, wells were aspirated on ice, briefly washed in 1 mL ice-
cold 0.9% sterile NaCl, and then extracted in a 1 mL solution of 80% methanol containing 
10 ng/mL phenylalanine-d8 as an internal standard. Subsequent steps were identical to those 
described above for profiling suspension cell samples. For CLF-PED-015T, cells were 
grown in the medium of interest for two passages prior to profiling to minimize the passage 
number at which they were profiled.
Primary AML cells—Following RBC removal from the primary leukemia specimen (See 
Primary Cell Isolation), a 1 mL aliquot of isolated cells was centrifuged at 21130 g for 15 
sec, resuspended in 10 mL of culture medium (RPMI+IFS or HPLM+dIFS) supplemented with 
human cytokines (See Cell Culture Conditions), and seeded equivalently across four wells of 
a 6-well plate. After 8 hr incubation, cells were pooled, centrifuged at 21130 g for 15 sec, 
and resuspended in 1 mL ice-cold 0.9% NaCl. From this resuspension, 100 μL was used to 
obtain the number and volume of viable cells in each sample using a Beckman Z2 Coulter 
Counter with a diameter setting of 5–24 μm. The remainder of cells were centrifuged at 
21130 g for 15 sec, and then extracted in a 1 mL solution of 80% methanol containing 10 
ng/mL phenylalanine-d8 as an internal standard. Subsequent steps were identical to those 
described above for profiling suspension cell samples.
NAD/NADH—For metabolite profiling whole-cell suspension samples to specifically 
quantify NAD and NADH, cells were pelleted and then seeded at a density of 200,000 
cells/mL in 6-well plates in 3 mL of fresh culture medium. After 24 hr incubation, cells were 
centrifuged at 250 g for 5 min, resuspended in 1 mL ice-cold 0.9% sterile NaCl, and again 
centrifuged at 250 g for 5 min at 4°C. Metabolites were extracted in a 500 μL solution of 
80% methanol containing 10 ng/mL phenylalanine-d8 as an internal standard. Following a 
10 min vortex and centrifugation for 3 min at 21130 g for 10 min at 4°C, samples were 
immediately injected for LC/MS analysis as described for whole-cell samples otherwise.
Metabolite profiling of UMPS Activity Assay—For metabolite profiling of UMPS 
activity assay samples, reaction mixtures were extracted (See UMPS Activity Assay) and 5 
μL of each sample was injected for LC/MS analysis as described otherwise, except that the 
mass spectrometer was operated in full scan, negative ionization mode only.
5-FU Treatment—NOMO1 cells were pelleted and then seeded at a density of 200,000 
cells/mL in 6-well plates in 3 mL of culture medium containing 20 μM 5-FU. After 24 hr 
incubation, metabolite extractions were performed identically to those described above for 
profiling suspension cell samples.
Quantification—A list of nearly 170 metabolites encompassing a variety of metabolic 
pathways and processes was created with the intention of exploring the metabolome in a 
global and targeted fashion. From a library of chemical standards assembled by the 
Whitehead Institute Metabolite Profiling core facility, we constructed six pools of standards 
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(See Table S1 for the composition of each pool) that together accounted for nearly 90% of 
this list. Standards were validated by LC/MS to confirm that they generated robust peaks at 
the expected m/z ratio. Stock solutions of each pool, containing 1 mM of each metabolite in 
water, were stored at −80°C. On the day of each run, these stocks were serially diluted in 
water, further diluted 1:10 into appropriate extraction solution, and then run in parallel with 
a given batch of biological samples.
Metabolite identification and quantification were performed with XCalibur QuanBrowser 
2.2 (Thermo Fisher Scientific) using a 10 ppm mass accuracy window and 0.5 min retention 
time window. To confirm metabolite identities and to enable quantification, the 
aforementioned pools of metabolite chemical standards were used. Typically, the final 
concentrations of standards were 10 nM, 100 nM, 1 μM, 10 μM, and 100 μM. For glucose, 
chemical standard solutions were also made at concentrations of 125 μM and 250 μM. For 
NAD and NADH, standards at 10 nM were omitted. For certain metabolites, chemical 
standards were utilized only for metabolite identification. For those metabolites lacking a 
chemical standard, peak identification was restricted to high confidence peak assignments 
(Smith et al., 2005). See Table S1.
Because metabolite extraction protocols differed by sample type, the concentration of 
phenylalanine-d8 in processed samples varied: chemical standard pools (9 ng/mL), media 
and plasma samples (9.75 ng/mL), and cell samples (100 ng/mL). Therefore, the raw peak 
area of phenylalanine-d8 within each sample of a given batch was first normalized to account 
for these differences. To quantitate metabolites, we first divided the raw peak area of each 
metabolite by its corresponding normalized phenylalanine-d8 peak area. From the 
normalized metabolite peak areas of a given chemical standard, we then generated a 
corresponding standard curve fit to a quadratic log-log equation, typically with r2 > 0.95, 
which was used to determine the metabolite concentration in each biological metabolite 
extract. The total number of moles of a metabolite in a particular whole-cell or medium/
plasma extract was then calculated from the sample concentration and the corresponding 
sample volume. Thus, final metabolite concentrations in biological samples were calculated 
using the appropriate equation below:
For those metabolites that were not quantified using a standard curve, normalized peak areas 
were used in the above calculations. For whole-cell profiles of adherent cell lines and 
primary AML cells, normalized peak areas were used for all metabolites.
Highly targeted metabolomics—For the highly targeted analyses of FdUMP and 
FUMP in whole-cell samples following 5-FU treatment, the instrument was run as described 
(See Media and Plasma), but with an additional tSIM (targeted selected ion monitoring) scan 
in negative ionization mode. The tSIM settings were as follows: resolution set to 70,000, an 
AGC target of 105, and a maximum integration time of 250 msec. The target masses were 
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325.0243 (corresponding to FdUMP) and 341.0192 (corresponding to FUMP). The isolation 
window around each target mass was set to 1.0 m/z.
For orotate, PRPP, OMP, and UMP in UMPS assay samples, all settings as described for the 
tSIM scan used for FdUMP and FUMP were identical except that the maximum integration 
time was 200 msec, and the target masses were 155.0098 (corresponding to orotate), 
323.0286 (corresponding to UMP), 367.0184 (corresponding to OMP), and 388.9445 
(corresponding to PRPP).
For NAD and NADH in whole-cell samples, all settings as described for the tSIM scan used 
for FdUMP and FUMP were identical except that the target masses were 662.1019 
(corresponding to NAD) and 664.1175 (corresponding to NADH).
For carbamoylaspartate, orotate, and orotidine in primary AML whole-cell samples, all 
settings as described for the tSIM scan used for FdUMP and FUMP were identical except 
that the target masses were 175.036 (corresponding to carbamoylaspartate), 155.0098 
(corresponding to orotate), and 287.0521 (corresponding to orotidine).
For pyruvate and succinate in media samples profiled following 24 hr cell culture, all 
settings as described for the tSIM scan used for FdUMP and FUMP were identical except 
that the target masses were 87.0088 (corresponding to pyruvate) and 117.0193 
(corresponding to succinate).
Labeling experiments
Cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 
mL of culture medium containing either 5 mM [U-13C]-glucose or 550 μM [α-15N]-
glutamine. After 24 hr incubation, metabolite extractions were performed identically to 
those described for profiling suspension cell samples (See Polar metabolite profiling and 
quantification of metabolite abundance).
For [α-15N]-glutamine tracing studies, the RPMI media were prepared using SILAC RPMI 
1640 Flex Media (Thermo Fisher Scientific A2494201), to which we added 5 mM glucose, 
14 μM phenol red, 1.15 mM arginine, 270 μM lysine, penicillin, streptomycin, and [α-15N]-
glutamine at the concentration noted above.
Lipidomics of culture media
LC/MS-based analyses were performed using the same QExactive benchtop orbitrap mass 
spectrometer and Dionex UltiMate 3000 UPLC system described otherwise (See Polar 
metabolite profiling and quantification of metabolite abundance).
For lipid profiling of media, 95 μL methanol and 190 μL dichloromethane were sequentially 
mixed by 20 sec vortex with 15 μL of medium. Following addition of 60 μL water to the 
mixture, samples were vortexed for 10 min at 4°C, and then centrifuged at 8000 g for 10 min 
at 4°C. From the resulting two-phase solution, 100 μL of the bottom (lipid) fraction was 
carefully collected and dried under nitrogen gas. Dried samples were stored at −80°C and 
then resuspended in a 50 μL solution of 65% acetonitrile, 30% isopropanol, and 5% water. 
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Following a 10 min vortex and centrifugation at 21130 g for 5 min at 4°C, 5 μL was injected 
onto an Ascentis Express C18 2.1 × 150 mm 2.7 μm column (Sigma-Aldrich).
Buffer A was a solution of 60% water, 40% acetonitrile, 10 mM ammonium formate 
(Sigma-Aldrich), and 0.1% formic acid (Pierce); buffer B was a solution of 90% 
isopropanol, 10% acetonitrile, 10 mM ammonium formate, and 0.1% formic acid. The 
chromatographic gradient was run at a flow rate of 0.260 mL/min as described previously 
((Hu et al., 2008): 0–1.5 min, isocratic elution with 32% B; from 1.5 to 4 min, increase to 
45% B; from 4 to 5 min, to 52% B; from 5 to 8 min, to 58% B; from 8 to 11 min, to 66% B; 
from 11 to 14 min, to 70% B; from 14 to 18 min, to 75% B; from 18 to 21 min, to 97% B; 
from 21 to 25 min, maintain at 97% B; from 25 to 25.1 min, decrease to 32% B and 
maintain for an additional 4.9 min for column re-equilibration. The column oven and 
autosampler tray were held at 55°C and 4°C, respectively. Separate injections for positive 
and negative ionization modes were made for each sample. The spray voltage was set to 4.2 
kV and the heated capillary and HESI were held at 320°C and 300°C, respectively. The S-
lens RF level was set to 50, and the sheath and auxiliary gas were set to 35 and 3 units, 
respectively. These conditions were held constant for both positive and negative ionization 
mode acquisitions. The MS data acquisition was performed in a full scan/data-dependent 
MS2 mode. For the full scan acquisition, the resolution was set to 70,000, the AGC target at 
106, the maximum integration time at 50 msec, and the scan range was 133.4–2000 m/z.
High-throughput identification and relative quantification of lipids was performed separately 
for positive and negative ionization mode data using LipidSearch software (Thermo Fisher 
Scientific) (Taguchi and Ishikawa, 2010; Yamada et al., 2013) using the default parameters 
for QExactive Product Search and Alignment. After alignment, raw peak areas for all 
identified lipids were exported to Microsoft Excel and filtered according to the following 
pre-determined quality control criteria: Rej (“Reject” parameter calculated by LipidSearch 
software) equal to 0; PQ (“Peak Quality” parameter calculated by LipidSearch software) 
greater than 0.85; CV (standard deviation divided by the average peak area across triplicate 
injections of a representative pooled biological sample) below 0.4; R (linear correlation 
across a three-point dilution series of the representative pooled sample) greater than 0.9. 
Raw peak areas of the filtered lipids were added to generate a “total lipid signal” for each 
sample, and individual lipid peak areas were normalized to this total signal as a control for 
extraction efficiency and sample loading. Normalized peak areas for all filtered lipids 
designated within a particular lipid class were then summed to represent the total signal of 
that class in the sample. Finally, for free fatty acids, peak areas were obtained using 
XCalibur QuanBrowser 2.2 (See Polar metabolite profiling and quantification of metabolite 
abundance) and normalized using the “total lipid signal” for the corresponding sample as 
well. See Table S1.
Cholesterol Quantification
Concentrations of total, LDL, and HDL cholesterol in IFS and dIFS were measured via 
enzymatic methods by the Yale Mouse Metabolic Phenotyping Center Analytical Core using 
a Cobas Mira Plus Analyzer (Roche Diagnostics). For total cholesterol, 3 μL of sample was 
added to 275 μL Cholesterol Rapid Liquid Reagent (Cliniqa R85464) and incubated at 37°C 
Cantor et al. Page 18
Cell. Author manuscript; available in PMC 2018 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
for 10 min prior to measurement of the absorbance at 500nm. For HDL cholesterol, 3 μL of 
sample was added to 180 μL HDL Cholesterol Direct Reagent 1 (Cliniqa R85549) and 60 μL 
HDL Cholesterol Direct Reagent 2 (Cliniqa R85549) and incubated at 37°C for 10 min prior 
to measurement of the absorbance at 600nm. For LDL cholesterol, 3 μL of sample was 
added to 225 μL LDL Direct Reagent 1 (Cliniqa R85556) and 75 μL LDL Direct Reagent 2 
(Cliniqa R85556) and incubated at 37°C for 10 min prior to measurement of the absorbance 
at 600nm. For quantification purposes, the Cobas analyzer was calibrated using two 
chemical controls.
Net exchange rates
At each time point that cell density was measured during the construction of a particular 
growth curve, a small aliquot of the culture was carefully removed, centrifuged at 250 g for 
5 min at 4°C, and metabolites were extracted from the supernatant as described for media 
and plasma samples, and then stored at −80°C (See Polar Metabolite Profiling and 
Metabolite Quantification). For a given growth curve, we profiled an extraction sample 
associated with a time point that fell in mid-exponential phase. We also profiled fresh media 
in parallel and the specific exchange rate for a given metabolite was obtained according to 
the simplified Monod model, q = μ/YX/S, which expands to: q = μ × V × (ΔM/ΔX), where μ 
is the specific growth rate, V is the culture volume, ΔM is the difference in metabolite 
concentration between the two time points, and ΔX is the difference in cell density between 
the two time points.
Metabolite composition of cultured media
Cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 
mL of fresh culture medium. After 24 hr incubation, a 100 μL aliquot of the culture was 
collected and centrifuged at 250 g for 5 min. Metabolites were then extracted from the 
supernatant as described for media and plasma samples, and then stored at −80°C (See Polar 
Metabolite Profiling and Metabolite Quantification).
Expression and Immunopurification of recombinant UMPS
For transfection of HEK-293T cells, 4 million cells were plated in 15 cm culture dishes. 
After 24 hr, cells were transfected with 15 μg of pLJC2-UMPS-3xFLAG or pLJC2-UMPS 
(Y37A, R155A)-3xFLAG using the polyethylenimine method (Boussif et al., 1995). After 
48 hr, cells were rinsed once with ice-cold PBS and then immediately lysed with lysis buffer 
(1% Triton X-100, 40 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 tablet of 
EDTA-free protease inhibitor (Roche 11580800; per 25 mL buffer), 1 tablet of PhosStop 
phosphatase inhibitor (Roche 04906845001; per 10 mL buffer)). The cell lysates were 
cleared by centrifugation at 21130 g for 10 min at 4°C. For anti-FLAG immunoprecipitation, 
the FLAG-M2 affinity gel (Sigma A2220) was washed 3 times in lysis buffer. For each 
experiment, 500 μL of a 50/50 slurry of the affinity gel was then added to a pool of clarified 
lysates collected from 5 individual 15 cm culture dishes, and incubated with rotation for 3 hr 
at 4°C. Following immunoprecipitation, the beads were washed 2 times in lysis buffer and 3 
times with lysis buffer containing 500 mM NaCl. Recombinant protein was then eluted in 
lysis buffer containing 1 mg/mL FLAG peptide for 1 hr at 4°C. The eluent was isolated by 
centrifugation at 100 g for 4 min at 4°C (BioRad micro bio-spin column 732-6204), buffer 
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exchanged (Amicon Ultra 30K NMWL) against 20 volumes of storage buffer (40 mM Tris-
HCl pH 7.5, 100 mM NaCl, 1.5 mM dTT), mixed with glycerol (final concentration 15% 
v/v), and finally snap-frozen with liquid nitrogen and stored at −80°C. Protein samples were 
quantified using Bradford reagent (Bio-Rad) and a BSA standard, and verified by 12% SDS-
PAGE.
UMPS Activity Assay
Reactions of each purified UMPS variant (20–40 nM enzyme) with orotate (100 μM) and 
PRPP (300 μM) were carried out at 37° C in 20 mM Tris-HCl pH 7.5, 5 mM Na2HPO4, 5 
mM MgCl2, 2 mM dTT, 100 μM EDTA (adapted from (Han et al., 1995)), and various 
concentrations of putative inhibitors in a total volume of 100 μL. Following 20 min 
incubation, a 15 μL aliquot of the reaction mixture was removed and immediately added to 
85 μL ice-cold 80% methanol for metabolite extraction, vortexed for 5 min, and centrifuged 
at 21130 g for 1 min at 4°C.
Stock solutions of 6-azauridine (Sigma-Aldrich A1882), 6-aza-UMP (Santa Cruz 
sc-291171), 9-methyluric acid (Santa Cruz sc-362184), allantoin (Sigma-Aldrich 05670), 
allopurinol (Sigma-Aldrich PHR1377), and uric acid (Sigma-Aldrich U2625) were made up 
fresh at 200 mM in 1 M NaOH, and upon appropriate dilutions, had little effect on reaction 
pH.
Using the peak areas of a UMP chemical standard (final concentrations 625 nM, 1.25 μM, 
2.5 μM, 5 μM, and 10 μM) identically prepared in 80% methanol, we generated a standard 
curve fit to a linear equation to ensure that UMP concentrations in the reaction samples did 
not exceed 10% of the initial orotate concentration. An OMP chemical standard was not 
available.
Drug Treatments
NOMO1 cells were seeded at a density of 16,667 cells/mL in 6-well plates in 3 mL of 
culture medium. After 24 hr incubation, cells were treated with 5-FU (Sigma-Aldrich 
F6627) (100 nM, 1 μM, 10 μM, 100 μM, or 1 mM) or doxorubicin (Sigma-Aldrich 44583) 
(1.95 nM, 7.81 nM, 31.25 nM, 125 nM, or 500 nM). All wells, including untreated controls, 
contained 0.5% DMSO. Following addition of drugs, plates were gently shaken for 2 min. 
After 4 days of treatment, 200 μL from each well was transferred to a white 96-well plate 
(Greiner) and cell viability was assessed with Cell Titer-Glo (Promega). Luminescence was 
measured with a SpectraMax M5 Plate Reader (Molecular Devices) and normalized to an 
untreated control.
SW620 cells were seeded in white 96-well plates (Greiner) at a density of 2000 cells/well 
and allowed to attach for 24 hr. 5-FU and doxorubicin were prepared in DMSO and 
dispensed using an HP D300 compound dispenser. Cell viability was assessed with Cell-
Titer Glo at 4 days following treatment and luminescence was measured as described above.
Dose-response values were plotted in GraphPad Prism and fit using a One Site-Fit logIC50 
equation.
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Cell lysis and immunoblotting
To evaluate mTORC1 signaling, cells cultured in a given medium were pelleted and then 
seeded in each of three wells of a 6-well plate at a density of 333,000/mL in 3 mL of 
corresponding fresh culture medium. After 2 hr incubation, cells were pooled, centrifuged at 
250 g for 5 min, resuspended in 1 mL ice-cold PBS, and again centrifuged at 250 g for 5 min 
at 4°C. Cells were then immediately lysed with lysis buffer (1% Triton X-100, 10 mM β-
glycerol phosphate, 10 mM pyrophosphate, 40 mM HEPES pH 7.4, 2.5 mM MgCl2, and 1 
table of EDTA-free protease inhibitor). The cell lysates were cleared by centrifugation at 
21130 g for 10 min at 4°C and then quantified for protein concentration using Bradford 
reagent. Protein samples were normalized for protein content, denatured by the addition of 
Laemmli buffer, boiled for 5 min, resolved by 8% SDS-PAGE, and transferred to a polyvinyl 
difluoride membrane (Millipore).
Membranes were blocked with 5% nonfat dry milk prepared in TBST for 1 hr at room 
temperature, then incubated with primary antibodies in 5% BSA overnight at 4°C. Primary 
antibodies to the following proteins were used at the indicated dilutions: Raptor (EMD 
Millipore 09-217; 1:1000); S6 kinase (Cell Signaling Technology 2708; 1:5000); and 
Phospho-S6 kinase (Thr389) (Cell Signaling Technology 9234; 1:1000). Membranes were 
washed with TBST three times for 5 min each, and then incubated with secondary antibody 
(Goat anti-Rabbit IgG HRP, Santa Cruz sc-2054; 1:5000) in 5% nonfat dry milk for 1 hr at 
room temperature. Membranes were washed again with TBST three times for 5 min each, 
and then visualized using chemiluminescence (Thermo Fisher Scientific).
Virus production and transduction efficiency
For transfection of HEK-293T cells, pLJM1-eGFP was co-transfected with the VSV-G 
envelope plasmid and the Delta-VPR lentiviral packaging plasmid using XTremeGene 9 
Transfection Reagent (Roche). Culture medium was exchanged 16 hr after transfection with 
the same medium instead supplemented with 20% IFS. The virus-containing supernatant 
was collected 48 hr after transfection and passed through a 0.45 μm filter to eliminate cells.
K562 cells were infected with eGFP lentivirus in culture medium containing 8 μg/mL 
polybrene (EMD Millipore) by centrifugation at 1200 g for 45 min at 37°C. After 24 hr 
incubation, cells were pelleted to remove virus and re-seeded into fresh culture medium. The 
efficiencies of transduction were evaluated 96 hr after infection by FACS (BD LSR Flow 
Cytometer) with gates applied to live cells that were GFP-positive.
Seahorse analysis
Oxygen consumption of intact cells was measured using an XF24 Extracellular Flux 
Analyzer (Seahorse Bioscience). XF24 Cell Culture Microplates (Seahorse Bioscience) were 
coated with a solution containing 0.08 mg/mL Cell-Tak (Corning), 90 μM NaHCO3, and 33 
μM NaOH to increase suspension cell adherence. After 20 min, all wells were washed twice 
with sterile water, and then seeded with either 200,000 (P12-Ichikawa, NOMO1, SEM) or 
125,000 (SUDHL4) total cells in a volume of 500 μL. Cells were attached by centrifugation 
at 600 g for 10 min with no brake, transferred to an incubator lacking CO2 for 30 min, and 
then transferred to a standard incubator. After 16 hr, basal oxygen consumption rates were 
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determined on the XF24 Analyzer and normalized by cell number as measured following the 
assay using a Beckman Z2 Coulter Counter with a diameter setting of 8–30 μm.
QUANTIFICATION AND STATISTICAL ANALYSIS
All p values were calculated using a two-tailed unpaired t test in GraphPad Prism 6. All CV 
and R values calculated for filtering lipids identified in LipidSearch were determined in 
Microsoft Excel. All specific growth rates and r values describing the relationship between 
rates of glucose consumption and lactate secretion were derived from linear regression 
analyses performed in GraphPad Prism 6. The exact value of n and the definition of center 
and precision measures are provided in all figure legends. All instances where n replicates 
are reported had n biological replicates, except the metabolite profiling data described for 
primary AML, for which n instead denotes technical replicates.
DATA AND SOFTWARE AVAILABILITY
Data resources
Datasets can be found in Tables S1, S2, and S3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
Systematic development of human plasma-like medium (HPLM)
Culture in HPLM has widespread effects on cellular metabolism
Culture in HPLM reveals uric acid as an endogenous inhibitor of UMPS
Uric acid can influence cellular sensitivity to 5-fluorouracil
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Figure 1. Figure 1, see also Figure S1 and Table S1: A cell culture medium that reflects the polar 
metabolite composition of human plasma
(A) Heatmap of relative concentrations of the indicated components of BME, MEM, 
DMEM, and RPMI 1640 compared to those in adult human plasma (log2-transformed fold 
changes). Components not present in a medium are marked as absent. See Table S1 for 
further detail regarding this heatmap and the concentrations of all metabolites.
(B) Schematic depicting the different metabolic milieus to which cells in culture and in vivo 
are exposed.
(C) Components of human plasma-like medium (HPLM). The concentrations of the 
components depicted by red-colored boxes reflect those in adult human plasma. See Table 
S1 for the detailed formulation of HPLM.
(D) Heatmap of relative concentrations of the indicated components in denoted media and 
mouse plasma compared to those in human plasma (log2-transformed fold changes). N/D, 
fold change value could not be determined. See Table S1 for detailed criteria used to 
generate this heatmap and for the concentrations of all metabolites. RPMI+IFS: RPMI 1640 
with 5 mM glucose and 10% IFS. RPMI+dIFS: RPMI 1640 with 5 mM glucose and 10% 
dialyzed IFS. HPLM+dIFS: HPLM containing 10% dialyzed IFS. *The following metabolites 
Cantor et al. Page 28
Cell. Author manuscript; available in PMC 2018 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
were not readily detected in media samples by the metabolite profiling method used: acetate, 
acetone, cysteine, formate, galactose, glutathione, and malonate.
(E) Relative growth rates of six hematological cancer cell lines cultured in HPLM+dIFS 
compared to in RPMI+IFS (blue) or in RPMI+dIFS (gray) (mean ± SD, n = 3; *p < 0.05) 
(left). Specific growth rates (μ) were calculated using natural log-transformed growth curves 
(right). Cell lines represent the following hematological cancers: K562 (chronic myeloid 
leukemia), KMS12BM (multiple myeloma), NOMO1 (acute myeloid leukemia), P12-
Ichikawa (T-cell acute lymphoblastic leukemia), SEM (B-cell acute lymphoblastic 
leukemia), SUDHL4 (B-cell lymphoma).
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Figure 2. Figure 2, see also Figure S2 and Table S2: Culture of cells in HPLM extensively alters 
their metabolic landscape
(A) Heatmap of relative intracellular metabolite concentrations following culture in 
HPLM+dIFS compared to that in RPMI+IFS (top six rows) or to RPMI+dIFS (bottom six 
rows). Within each group, metabolites are sorted by average log2-transformed fold change of 
the top six rows (n = 3). N/D, fold change value could not be determined because the 
metabolite was not readily detected following culture in one or more of the media. To be 
included in the heatmap, metabolites had to have a fold change measured in at least four of 
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the six cell lines. See Table S2 for detailed criteria used to generate this heatmap, metabolite 
abbreviations, and the concentrations of all metabolites.
(B) Energy charge values, as calculated by the displayed equation, following culture in 
HPLM+dIFS compared to that in RPMI+IFS (blue) or to RPMI+dIFS (gray) (mean ± SD, n = 
3).
(C) Intracellular GSH/GSSG ratios following culture in HPLM+dIFS compared to that in 
RPMI+IFS (blue) or to RPMI+dIFS (gray) (mean ± SD, n = 3, *p < 0.05).
(D) Intracellular NAD/NADH ratios following culture in HPLM+dIFS compared to that in 
RPMI+IFS (blue) or to RPMI+dIFS (gray) (mean ± SEM, n = 3, *p < 0.05).
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Figure 3. Figure 3, see also Figure S3 and Table S2: Culture of cells in HPLM+dIFS affects the 
utilization of glucose carbons and the α-amino nitrogen of glutamine
(A) Schematic depicting the incorporation of 13C from glucose into pathways branching 
from glycolysis and into pyruvate, and various fates of glucose-derived carbon from 
pyruvate and Acetyl-CoA, including into the TCA cycle. See Table S2 for 13C labeling 
patterns for metabolites in blue. G1P: glucose 1-phosphate. G6P: glucose 6-phosphate. F6P: 
fructose 6-phosphate. DHAP: dihydroxyacetone phosphate. GPC: glycerophosphocholine. 
PDH: pyruvate dehydrogenase. LDH: lactate dehydrogenase. GPT: alanine 
aminotransferase.
(B) Fraction of pyruvate labeled with three 13C (M3) following culture of cells in 
HPLM+dIFS (red) or RPMI+IFS (gray) (mean ± SD, n = 3).
(C) Fraction of citrate labeled with two 13C (M2) following culture of cells in HPLM+dIFS 
(red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(D) Fraction of GPC labeled with three 13C (M3) following culture of cells in HPLM+dIFS 
(red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(E) Fraction of F6P/G1P labeled with six 13C (M6) following culture of cells in HPLM+dIFS 
(red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
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(F) Fraction of alanine labeled with three 13C (M3) following culture of cells in HPLM+dIFS 
(red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(G) Schematic depicting the transaminase-mediate transfer of 15N from the α-amino 
nitrogen of glutamine onto various amino acids. See Table S2 for 15N labeling patterns for 
amino acids in blue.
(H) Fraction of alanine labeled with one 15N (M1) following culture of cells in HPLM+dIFS 
(red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(I) Fraction of asparagine labeled with one 15N (M1) following culture of cells in 
HPLM+dIFS (red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(J) Fraction of valine labeled with one 15N (M1) following culture of cells in HPLM+dIFS 
(red) or RPMI+IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
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Figure 4. Figure 4, see also Figure S4: Culture in HPLM+dIFS greatly affects the intracellular 
abundances of metabolites involved in pyrimidine metabolism
(A–D) Relative intracellular abundances of carbamoylaspartate (A), dihydroorotate (B), 
orotate (C), and orotidine (D) following culture of cells in HPLM+dIFS compared to that in 
RPMI+IFS (blue) or RPMI+dIFS (red) (mean ± SD, n = 3; p < 0.0005 for all bars).
(E) Schematic depicting the de novo pyrimidine synthesis pathway. NT: nucleotidase.
(F and G) Relative intracellular abundances of CTP (F) and UTP (G) following culture of 
cells in HPLM+dIFS compared to that in RPMI+IFS (blue) or RPMI+dIFS (gray) (mean ± SD, 
n = 3, **p < 0.0005).
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Figure 5. The uric acid component of HPLM+dIFS mediates the effects of HPLM+dIFS on 
pyrimidine metabolism
(A) Composition of minimal HPLM (top) and list of components removed from HPLM+dIFS 
to generate the indicated dropout formulations (bottom).
(B) Relative intracellular abundances of orotate (top) and orotidine (bottom) following 
culture of cells in each HPLM+dIFS derivative or minimal HPLM (MH) compared to that in 
complete HPLM+dIFS (mean ± SD, n = 3). The number designations of the HPLM+dIFS 
derivatives correspond to those in panel A.
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(C) Concentrations of uric acid in RPMI+IFS and HPLM+dIFS as measured by LC/MS-based 
metabolite profiling (n = 4). Uric acid could not be readily detected in RPMI+dIFS by the 
metabolite profiling method used. Thus, the indicated concentration for RPMI+dIFS 
approximately corresponds to that of minimum detection in media samples.
(D) Intracellular concentrations of uric acid following culture of cells in RPMI+IFS, 
RPMI+dIFS, or HPLM+dIFS (mean ± SD, n = 3).
(E) Relative intracellular abundances of orotate and orotidine following culture of K562 
cells in HPLM+dIFS containing increasing concentrations of uric acid compared to that in 
standard HPLM+dIFS, which contains 350 μM uric acid (mean ± SD, n = 3).
(F) Relative intracellular abundances of orotate, orotidine (left) (mean ± SD, n = 3; p < 
0.0005 for all bars), and UTP (mean ± SD, n = 3; *p < 0.005; **p < 0.0005) (right) 
following culture of cells in RPMI+IFS supplemented with 350 μM uric acid compared to 
that in RPMI+IFS.
(G) Relative intracellular abundances of carbamoylaspartate, dihydroorotate, orotate, and 
orotidine following culture of K562 cells in HPLM+dIFS containing either 350 μM uric acid 
(red) or 350 μM uric acid 9-methyluric acid (9-MUA) (white) compared to that in 
HPLM+dIFS lacking uric acid (mean ± SD, n = 3).
(H) Schematic depicting the pathways that influence the plasma concentrations of uric acid; 
1: glomerular filtration (70%), 2: secretion (10%), 3: reabsorption (90%), 4: excretion (30%) 
(Bobulescu and Moe, 2012). In contrast to most mammals, humans and many higher 
primates lack uricase (UOX) activity, which converts uric acid to allantoin (left). 
Concentrations of uric acid and allantoin in mouse plasma as measured by metabolite 
profiling in this study (n = 4). Average concentration of uric acid in human plasma 
calculated from annotated values in the Human Metabolome Database. Concentration of 
allantoin in human plasma as reported elsewhere (Kand’ár and Záková, 2008) (right).
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Figure 6. Figure 6, see also Figures S5 and S6: Uric acid is a direct inhibitor of UMPS
(A) Schematic depicting the reactions catalyzed by each domain of bifunctional UMP 
synthase (UMPS). OPRT: orotate phosphoribosyltransferase. ODC: OMP decarboxylase.
(B) Schematic depicting competitive inhibition of the ODC domain of UMPS by allopurinol 
ribonucleotide (top) and 6-aza-UMP (bottom). Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) catalyzes the conversion of allopurinol to its 
ribonucleotide derivative, and uridine-cytidine kinase (UCK) catalyzes that of 6-azauridine 
to 6-aza-UMP.
(C) Quantification of OMP (left) and UMP (right) following incubation of recombinant 
UMPS (WT or the Y37A, R155A mutant) with its substrates orotate and PRPP at the 
indicated concentrations (mean ± SD, n = 3). WT: wild-type.
(D) Relative abundances of OMP (left) and UMP (right) following addition of increasing 
concentrations of 6-aza-UMP or vehicle to the UMPS activity assay (mean ± SD, n = 3).
(E) Relative abundances of OMP (left) and UMP (middle) following addition of increasing 
concentrations of uric acid or vehicle to the UMPS activity assay (mean ± SD, n = 3). 
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Schematic depicting competitive inhibition of the ODC domain of UMPS by uric acid 
(right).
(F) Relative abundances of OMP (left) and UMP (right) following addition of 9-methyluric 
acid, allantoin, allopurinol, 6-azauridine, uric acid, or vehicle to the UMPS activity assay 
(mean ± SD, n = 3).
Cantor et al. Page 38
Cell. Author manuscript; available in PMC 2018 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. Figure 7, see also Figure S7: Uric acid antagonizes the cytotoxicity of 5-fluorouracil
(A) Schematic depicting the metabolism of 5-fluorouracil (5-FU) (top). 5-FU is converted 
into various fluoronucleotide derivatives that mediate its cytotoxic effects. Fluorouridine 
triphosphate (FUTP) and fluorodeoxyuridine triphosphate lead to cell death upon 
misincorporation into RNA and DNA, respectively. Fluorodeoxyuridine monophosphate 
(FdUMP) leads to cell death by inhibition of thymidylate synthase (TYMS) (Longley et al., 
2003). Enzymes depicted are uridine phosphorylase (UPP), uridine-cytidine kinase (UCK), 
thymidine phosphorylase (TYMP), thymidine kinase (TK), and ribonucleotide reductase 
(RRM). Other metabolites indicated are fluorouridine (FUR), fluorouridine monophosphate 
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(FUMP), fluorouridine diphosphate (FUDP), fluorodeoxyuridine (FUDR), and 
fluorodeoxyuridine diphosphate (FdUDP). The OPRT domain of UMPS catalyzes the direct 
conversion of 5-FU to FUMP (bottom).
(B) Schematic showing that the OPRT domain of UMPS catalyzes the conversions of orotate 
to OMP and 5-FU to FUMP.
(C and D) Dose-response of NOMO1 cells to 5-FU (C) or doxorubicin (D) when cultured in 
RPMI+IFS (dark gray), RPMI+dIFS (light gray), or HPLM+dIFS (red) (mean ± SD, n = 9). 
Data points are the average of three independent biological experiments that each consisted 
of three technical replicates (left). EC50 of 5-FU (C) or doxorubicin (D) in NOMO1 cells 
when cultured in RPMI+IFS (dark gray), RPMI+dIFS (light gray), or HPLM+dIFS (red). 
Horizontal bar indicates the mean of three independent biological experiments; * p < 0.001; 
ns: not significant (right).
(E and F) Dose-response of NOMO1 cells to 5-FU (E) or doxorubicin (F) when cultured in 
HPLM+dIFS (green) or HPLM+dIFS lacking uric acid (blue) (mean ± SD, n = 9). Data points 
are the average of three independent biological experiments that each consisted of three 
technical replicates (left). EC50 of 5-FU (C) or doxorubicin (D) in NOMO1 cells when 
cultured in HPLM+dIFS (red) or HPLM+dIFS lacking uric acid (blue). Horizontal bar 
indicates the mean of three independent biological experiments; * p < 0.001; ns: not 
significant (right).
(G) Intracellular abundances of 5-FU (left), FdUMP (middle), and FUMP (right) in NOMO1 
cells treated with 20 μM 5-FU and cultured for 24 hr in HPLM+dIFS (red) or HPLM+dIFS 
lacking uric acid (blue) (mean ± SD, n = 3). ND: not detected.
(H) Proposed mechanism of uric acid-mediated antagonism of cytotoxicity caused by 5-FU. 
As either the OPRT domain of UMPS or the sequential actions of UPP and UCK can convert 
5-FU to FUMP, the influence of uric acid on 5-FU sensitivity likely depends on the extent 
that a given cell type generates FUMP via OPRT-mediated synthesis.
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